Publication Author: Zeliadt_Steven
-
Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis.
Li C, Zeliadt SB, Hall IJ, Smith JL, Ekwueme DU, Moinpour CM, Penson DF, Thompson IM, Keane TE, Ramsey SD. Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. Value Health. 2012 Jul-Aug;15(5)
rakerr2
-
Complementary and alternative medicine use, patient-reported outcomes, and treatment satisfaction among men with localized prostate cancer.
Ramsey SD, Zeliadt SB, Blough DK, Fedorenko CR, Fairweather ME, McDermott CL, Penson DF, Van Den Eeden SK, Hamilton AS, Arora NK. Complementary and Alternative Medicine Use, Patient-reported Outcomes, and Treatment Satisfaction Among Men With Localized Pr
rakerr2
-
Complementary and alternative medicine use among newly diagnosed prostate cancer patients.
McDermott CL, Blough DK, Fedorenko CR, Arora NK, Zeliadt SB, Fairweather ME, Oakley-Girvan I, Van Den Eeden SK, Ramsey SD. Complementary and alternative medicine use among newly diagnosed prostate cancer patients. Support Care Cancer. 2012 Jan;20(1):65-73
rakerr2
-
Biopsy follow-up of prostate-specific antigen tests.
Zeliadt SB, Buist DS, Reid RJ, Grossman DC, Ma J, Etzioni R. Biopsy follow-up of prostate-specific antigen tests. Am J Prev Med. 2012 Jan;42(1):37-43.
rakerr2
-
Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest.
Zeliadt SB, Sekaran NK, Hu EY, Slatore CC, Au DH, Backhus L, Wu DY, Crawford J, Lyman GH, Dale DC. Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer i
rakerr2
-
Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer.
Zeliadt SB, Penson DF, Moinpour CM, Blough DK, Fedorenko CR, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD. Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU Int
rakerr2
-
Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US population.
Rim SH, Hall IJ, Fairweather ME, Fedorenko CR, Ekwueme DU, Smith JL, Thompson IM, Keane TE, Penson DF, Moinpour CM, Zeliadt SB, Ramsey SD. Considering racial and ethnic preferences in communication and interactions among the patient, family member, and ph
rakerr2
-
Influence of publication of US and European prostate cancer screening trials on PSA testing practices.
Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst. 2011 Mar 16;103(6):520-3. Epub 2011 Feb 28.
rakerr2
-
Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions.
Ramsey SD, Zeliadt SB, Fedorenko CR, Blough DK, Moinpour CM, Hall IJ, Smith JL, Ekwueme DU, Fairweather ME, Thompson IM, Keane TE, Penson DF. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for init
rakerr2
-
What happens after an elevated PSA test: the experience of 13,591 veterans.
Zeliadt SB, Hoffman RM, Etzioni R, Ginger VA, Lin DW. What happens after an elevated PSA test: the experience of 13,591 veterans. J Gen Intern Med. 2010 Nov;25(11):1205-10. Epub 2010 Aug 10.
rakerr2